399 related articles for article (PubMed ID: 29691282)
1. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, biological evaluation and molecular docking studies of new chalcone derivatives containing diaryl ether moiety as potential anticancer agents and tubulin polymerization inhibitors.
Wang G; Liu W; Gong Z; Huang Y; Li Y; Peng Z
Bioorg Chem; 2020 Jan; 95():103565. PubMed ID: 31927336
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of millepachine derivatives as a new class of tubulin polymerization inhibitors.
Wang G; Peng F; Cao D; Yang Z; Han X; Liu J; Wu W; He L; Ma L; Chen J; Sang Y; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2013 Nov; 21(21):6844-54. PubMed ID: 23993668
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation, and molecular modelling of new naphthalene-chalcone derivatives as potential anticancer agents on MCF-7 breast cancer cells by targeting tubulin colchicine binding site.
Wang G; Liu W; Gong Z; Huang Y; Li Y; Peng Z
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):139-144. PubMed ID: 31724435
[TBL] [Abstract][Full Text] [Related]
5. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.
Yan J; Zhuang Q; Li Z; Xiong Y; He M; Kang C; Zhang Q; Han L; Liang E; Liu H; Ke P; Huang X
Eur J Pharmacol; 2021 May; 898():173975. PubMed ID: 33647258
[TBL] [Abstract][Full Text] [Related]
6. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel non-toxic and anti-angiogenic α-fluorinated chalcones as potent colchicine binding site inhibitors.
Sun M; Yuan M; Kang Y; Qin J; Zhang Y; Duan Y; Wang L; Yao Y
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):339-354. PubMed ID: 34979843
[TBL] [Abstract][Full Text] [Related]
9. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
10. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular docking and biological evaluation of 1-phenylsulphonyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as novel potential tubulin assembling inhibitors.
Wang YT; Cai XC; Shi TQ; Zhang YL; Wang ZC; Liu CH; Zhu HL
Chem Biol Drug Des; 2017 Jul; 90(1):112-118. PubMed ID: 28032450
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
Wang G; Li C; He L; Lei K; Wang F; Pu Y; Yang Z; Cao D; Ma L; Chen J; Sang Y; Liang X; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2014 Apr; 22(7):2060-79. PubMed ID: 24629450
[TBL] [Abstract][Full Text] [Related]
13. SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines.
Yan W; Yang T; Yang J; Wang T; Yu Y; Wang Y; Chen Q; Bai P; Li D; Ye H; Qiu Q; Zhou Y; Hu Y; Yang S; Wei Y; Li W; Chen L
Cell Physiol Biochem; 2018; 47(2):489-504. PubMed ID: 29794416
[TBL] [Abstract][Full Text] [Related]
14. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel 5-(4-chlorophenyl)furan derivatives with inhibitory activity on tubulin polymerization.
Moussa SA; A Osman EE; Eid NM; Abou-Seri SM; El Moghazy SM
Future Med Chem; 2018 Aug; 10(16):1907-1924. PubMed ID: 29966433
[TBL] [Abstract][Full Text] [Related]
17. Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance.
Cheng B; Zhu G; Meng L; Wu G; Chen Q; Ma S
Eur J Med Chem; 2022 Jan; 228():113930. PubMed ID: 34794817
[TBL] [Abstract][Full Text] [Related]
18. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation and molecular docking studies of a new series of chalcones containing naphthalene moiety as anticancer agents.
Wang G; Qiu J; Xiao X; Cao A; Zhou F
Bioorg Chem; 2018 Feb; 76():249-257. PubMed ID: 29197743
[TBL] [Abstract][Full Text] [Related]
20. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
